Media

Four new ANDA approvals during past month • Near-completion of first phase of manufacturing expansion, doubling current manufacturing capacity • New Head of Supply Chain

MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ — Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug development operations announced today that in order to meet demand for its products (approved and near term) the company has fortified its supply chain, increased manufacturing capacity and strengthened its management team. 

During the past two months, Tris has been fortunate to receive five new ANDA approvals from the FDA, beginning with the first-ever generic of Delsym^®. Furthermore, Tris has several ANDAs and two NDAs pending FDA approval. Tris initiated an expansion of its manufacturing capacity earlier this year and is roughly midway through a 15 month expansion which will take the company’s footprint from its current 90,000 sq. ft. to approximately 200,000 sq. ft. The first phase will double the cGMP capacity and help Tris stay ahead of its growing manufacturing requirements.

Ketan Mehta, Tris’ President and CEO said, “Expanding manufacturing capacity is a critical part of the growth equation but equally important is having the right team to manage our dynamic and complex supply chain. To that end, we have added several new managerial positions and were very fortunate to have recruited David Palew, a seasoned supply chain executive, for the newly created position of Senior Director of Supply Chain.”

Dave Palew brings to Tris over 15 years of supply chain experience at large pharmaceutical companies such as Block Drug, Alpharma, Barr/Teva and G&W Laboratories. David will lead our growing supply chain team, co-lead our ERP implementation team and work closely with all our suppliers and external marketing partners.

Delsym is a registered trademark of Reckitt Benckiser, which is not associated with Tris Pharma or Tris’ generic product.

About Tris Pharma:

Tris Pharma is an emerging specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris’ Nobuse^™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris’ R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit https://www.trispharma.com